Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); U.S. Tali Approval May Unlock Potential
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $1.20 +1.69%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 11 | New: 13
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX) price target of $8.00.
Analyst, Ritu Baral, said, "We see good chance of May 2012 tali US approval, Q2/12 US launch, mid--2012 EU approval. We think PLX’s taliglucerase (tali) will be approved on its May 1 PDUFA date and may get ~15% of the $1.2B+ WW Gaucher’s market, with an ex-US competitive pricing focus given resolution of the Gaucher’s ERT shortage."
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.23 yesterday.
Analyst, Ritu Baral, said, "We see good chance of May 2012 tali US approval, Q2/12 US launch, mid--2012 EU approval. We think PLX’s taliglucerase (tali) will be approved on its May 1 PDUFA date and may get ~15% of the $1.2B+ WW Gaucher’s market, with an ex-US competitive pricing focus given resolution of the Gaucher’s ERT shortage."
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades UBS AG (UBSG:SW) (UBS) to Neutral
- Fiserv (FI) PT Raised to $175 at TD Cowen
- Costco Wholesale (COST) PT Raised to $710 at Citi
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
